Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrially encoded tRNA lysine (MT-TK) is a small, non-coding transfer RNA encoded by the mitochondrial genome. It consists of 70 nucleotides and is responsible for delivering lysine to the growing polypeptide chain during mitochondrial translation. This RNA plays a critical role in the synthesis of proteins required for oxidative phosphorylation, the primary pathway through which mitochondria produce ATP. Mutations in the MT-TK gene, especially the m.8344A>G mutation, are causative for myoclonic epilepsy with ragged-red fibers (MERRF) syndrome and other mitochondrial diseases. Proper post-transcriptional modifications and structural folding of MT-TK are essential for its function and for the overall integrity of mitochondrial translation.
Not applicable (no drugs are known to directly target mitochondrial tRNAs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded tRNA lysine (MT-TK).